Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPagliflozin in Acute Myocardial Infarction (Heart Failure Hospitalisation and Mortality)
2019-001037-13Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Empagliflozin arm with Placebo arm (2 arms). Primary endpoint: Composite of time to first hospitalization for heart failure or all-cause mortality. Started Nov 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2019-001037-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001037-13.